Selecting chemotherapy schedules for adjuvant treatment of early stage breast cancer, what is the rationale behind

سال انتشار: 1394
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 310

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RCM-2-3_005

تاریخ نمایه سازی: 2 دی 1398

چکیده مقاله:

Breast cancer is one of the most prevalent cancers that oncologists are faced with in their clinics. The varieties of clinical features of the disease result to very different scenarios in the processes of treatment decision making. While classic factors of stage, grade, age and hormone receptor status are still the criterion for choosing treatment, a very delicate list of other prognostic and predictive factors have been entered to this field over recent two decades. The evidence-based medicine rules to treat patients based on the best evidences that have been found by powered randomized clinical trials. Different panels and guidelines gathering these evidences try to help oncologists to find the best treatment methods through the variable and sometimes contradicting results. As it is always the main objective, increasing the survival rates in addition to the ideal aim of curing the disease is usually the target.  Finding the best and the most practical chemotherapy regimen against breast cancer needs to notice the biology of this disease and its varieties along with each individual patient condition. It is clear that not all patients need the most complicated and expensive treatment.

کلیدواژه ها:

Adjuvant treatment ، Chemotherapy schedules ، Early stage breast cancer

نویسندگان

Roham Salek

Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Narges Bayat Mokhtari

Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Soudabeh Shahidsales

Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Group EBCTC. Effects of chemotherapy and hormonal therapy for early ...
  • Group EBCTC. Treatment of early breast cancer. 1. Worldwide evidence ...
  • Group EBCTC. Polychemotherapy for early breast cancer: an overview of ...
  • Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status ...
  • Piccart M. Controversies in adjuvant systemic therapy for breast cancer. ...
  • Network. NCC. National Comprehensive Cancer Network. Clinical practice guidelines in ...
  • The European Society For Medical Oncology. ESMO Clinical Practice Guidelines: ...
  • Goldhirsch A, Winer E, Coates A, et al. Personalizing the ...
  • Group EBCTC. Comparisons between different polychemotherapy regimens for early breast ...
  • Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes ...
  • Trudeau M, Charbonneau F, Gelmon K, et al. Selection of ...
  • Henderson I, Berry D, Demetri G, et al, editors. Improved ...
  • Budman D, Wood W, Henderson I, et al, editors. Initial ...
  • Mamounas EP. NSABP breast cancer clinical trials: recent results and ...
  • Piccart MJ, Di Leo A, Beauduin M, et al. Phase ...
  • de Azambuja E, Paesmans M, Beauduin M, et al. Long-term ...
  • Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial ...
  • Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial ...
  • Group FAS. Benefit of a high-dose epirubicin regimen in adjuvant ...
  • Bonneterre J, Roché H, Kerbrat P, et al. Epirubicin increases ...
  • Galligioni E, Cetto G, Nascimben O, et al, editors. Adjuvant ...
  • Bria E, Nistico C, Cuppone F, et al. Benefit of ...
  • Citron ML, Berry DA, Cirrincione C, et al. Randomized trial ...
  • Sparano J, Wang M, Martino S, et al, editors. Phase ...
  • Swain S, Jeong J, Geyer C, et al. NSABP B-30: ...
  • Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles ...
  • Bayraktar S, Arun B. Dose-Dense Chemotherapy for Breast Cancer. Breast ...
  • Kurkjian C, Ozer. H. Management of adverse effects of treatment; ...
  • Fisher B, Jeong J-H, Bryant J, et al. Treatment of ...
  • Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with ...
  • Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled ...
  • Paik S, Taniyama Y, Geyer CE. Anthracyclines in the treatment ...
  • Gennari A, Sormani MP, Pronzato P, et al. HER2 status ...
  • Hayes DF, Thor AD, Dressler LG, et al. HER2 and ...
  • Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, ...
  • Muss HB, Berry DA, Cirrincione C, et al. Toxicity of ...
  • Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel ...
  • Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function ...
  • Campbell JD, Ramsey SD. The costs of treating breast cancer ...
  • نمایش کامل مراجع